BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 31806050)

  • 1. Man or machine? Prospective comparison of the version 2018 EASL, LI-RADS criteria and a radiomics model to diagnose hepatocellular carcinoma.
    Jiang H; Liu X; Chen J; Wei Y; Lee JM; Cao L; Wu Y; Duan T; Li X; Ma L; Song B
    Cancer Imaging; 2019 Dec; 19(1):84. PubMed ID: 31806050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of small (≤ 3 cm) hepatocellular carcinomas from benign nodules in cirrhotic liver: the added additive value of MRI-based radiomics analysis to LI-RADS version 2018 algorithm.
    Zhong X; Guan T; Tang D; Li J; Lu B; Cui S; Tang H
    BMC Gastroenterol; 2021 Apr; 21(1):155. PubMed ID: 33827440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules.
    Mokrane FZ; Lu L; Vavasseur A; Otal P; Peron JM; Luk L; Yang H; Ammari S; Saenger Y; Rousseau H; Zhao B; Schwartz LH; Dercle L
    Eur Radiol; 2020 Jan; 30(1):558-570. PubMed ID: 31444598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-individual comparison of dual portal venous phases for non-invasive diagnosis of hepatocellular carcinoma at gadoxetic acid-enhanced liver MRI.
    Kang HJ; Lee JM; Jeon SK; Jang S; Park S; Joo I; Yoon JH; Han JK
    Eur Radiol; 2021 Feb; 31(2):824-833. PubMed ID: 32845387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.
    Ren AH; Zhao PF; Yang DW; Du JB; Wang ZC; Yang ZH
    J Magn Reson Imaging; 2019 Sep; 50(3):746-755. PubMed ID: 30648327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
    Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
    AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
    [No Abstract]   [Full Text] [Related]  

  • 8. Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
    Lee S; Kim MJ; Kim SS; Shin H; Kim DY; Choi JY; Park MS; Mitchell DG
    Hepatol Int; 2020 Jan; 14(1):70-79. PubMed ID: 31802388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017).
    Ding Y; Rao SX; Wang WT; Chen CZ; Li RC; Zeng M
    Cancer Imaging; 2018 Dec; 18(1):48. PubMed ID: 30526674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the diagnostic performance of imaging criteria for HCCs ≤ 3.0 cm on gadoxetate disodium-enhanced MRI.
    Byun J; Choi SH; Byun JH; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    Hepatol Int; 2020 Jul; 14(4):534-543. PubMed ID: 32314171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Performance of the 2018 EASL vs. LI-RADS for Hepatocellular Carcinoma Using CT and MRI: A Systematic Review and Meta-Analysis of Comparative Studies.
    Shin J; Lee S; Yoon JK; Roh YH
    J Magn Reson Imaging; 2023 Dec; 58(6):1942-1950. PubMed ID: 37010244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Korean J Radiol; 2021 Jul; 22(7):1066-1076. PubMed ID: 33739633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of LI-RADS with other non-invasive liver MRI criteria and radiological opinion for diagnosing hepatocellular carcinoma in cirrhotic livers using gadoxetic acid with histopathological explant correlation.
    Clarke CGD; Albazaz R; Smith CR; Rowe I; Treanor D; Wyatt JI; Sheridan MB; Guthrie JA
    Clin Radiol; 2021 May; 76(5):333-341. PubMed ID: 33461746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suboptimal performance of LI-RADS v2018 on gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in liver transplant candidates.
    Oh NE; Choi SH; Kim S; Lee H; Jang HJ; Byun JH; Won HJ; Shin YM
    Eur Radiol; 2024 Jan; 34(1):465-474. PubMed ID: 37532900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the current guidelines for diagnosing hepatocellular carcinoma using gadoxetic acid-enhanced magnetic resonance imaging.
    Hwang SH; Park MS; Park S; Lim JS; Kim SU; Park YN
    Eur Radiol; 2021 Jul; 31(7):4492-4503. PubMed ID: 33409787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018.
    Ludwig DR; Fraum TJ; Cannella R; Ballard DH; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ
    Abdom Radiol (NY); 2019 Jun; 44(6):2116-2132. PubMed ID: 30798397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid-enhanced MRI in transplantation candidates.
    Jeon SK; Lee JM; Joo I; Yoo J; Park JY
    Eur Radiol; 2020 Sep; 30(9):4762-4771. PubMed ID: 32333148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI.
    Wang W; Gu D; Wei J; Ding Y; Yang L; Zhu K; Luo R; Rao SX; Tian J; Zeng M
    Eur Radiol; 2020 May; 30(5):3004-3014. PubMed ID: 32002645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective analysis of current guidelines for hepatocellular carcinoma diagnosis on gadoxetic acid-enhanced MRI in at-risk patients.
    Park SH; Shim YS; Kim B; Kim SY; Kim YS; Huh J; Park JH; Kim KW; Lee SS
    Eur Radiol; 2021 Jul; 31(7):4751-4763. PubMed ID: 33389037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
    Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
    World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.